Local recurrence in mismatch repair-proficient colon cancer predicted by an infiltrative tumor border and lack of CD8+ tumor-infiltrating lymphocytes

Clinical Cancer Research

Volumn 14, Issue 12, 2008, Pages 3792-3797

  Zlobec, Inti ^a   M terracciano, Luigi ^a   Lugli, Alessandro ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOTIC PROTEASE ACTIVATING FACTOR 1; BETA CATENIN; CD8 ANTIGEN; CYCLOOXYGENASE 2; EPHRIN RECEPTOR B2; EPIDERMAL GROWTH FACTOR RECEPTOR; KI 67 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; MUCIN 1; MUCIN 2; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6; PROTEIN P21; PROTEIN P27; PROTEIN P53; SMAD4 PROTEIN; TUMOR MARKER; UROKINASE; UROKINASE RECEPTOR; UVOMORULIN; VASCULOTROPIN;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; COLON CANCER; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MISMATCH REPAIR; PATHOLOGY; PREDICTIVE VALIDITY; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; CANCER INVASION; CD8+ T LYMPHOCYTE; COLON TUMOR; DECISION SUPPORT SYSTEM; EVALUATION; GENETICS; IMMUNOLOGY; PROGNOSIS; ROC CURVE; SENSITIVITY AND SPECIFICITY; SURVIVAL; TUMOR RECURRENCE;

CD8-POSITIVE T-LYMPHOCYTES; COLONIC NEOPLASMS; DECISION SUPPORT TECHNIQUES; DNA MISMATCH REPAIR; FEMALE; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; ROC CURVE; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS;

EID: 52449111110     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0048     Document Type: Article

References (43)

1. Hollstein M, Sidransky D,Vogelstein B. Harris CC. p53 mutations in human cancers. Science 1991;253:49 - 53.
2. Wiggers T, Arends JW, Schutte B,Volovics L, Bosman FT. A multivariate analysis of pathologic prognostic indicators in large bowel cancer. Cancer 1988;61: 386-95.
3. Wolpin BM, Meyerhardt JA, Mamon HJ, Mayer RJ. Adjuvant treatment of colorectal cancer. CA Cancer J Clin 2007;57:168-85.
4. Andreoni B, Chiappa A, Bertani E, et al. Surgical outcomes for colon and rectal cancer over a decade: results from a consecutive monocentric experience in 902 unselected patients. World J Surg Oncol 2007;5:73.
5. Heald RJ, Ryall RD. Recurrence and survival after total mesorectal excision for rectal cancer. Lancet 1986;1:1479-82.
6. Peeters KC, Marijnen CA, Nagtegaal ID, et al. The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg 2007;246:693-701.
7. Wong RK, Tandan V, De Silva S, Figueredo A. Preoperative radiotherapy and curative surgery for the management of localized rectal carcinoma. Cochrane Database Syst Rev 2007: CD002102.
8. Glynne-Jones R, Mawdsley S, Novell JR. The clinical significance of the circumferential resection margin following preoperative pelvic chemo-radiotherapy in rectal cancer: why we need a common language. Colorectal Dis 2006;8:800-7.
9. Rodel C, Martus P, PapadoupolosT, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 2005;23:8688-96.
10. Laurie JA, Moertel CG, Fleming TR, et al. Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol 1989;7:1447-56.
11. Moertel CG, Fleming TR, Macdonald JS, etal. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990;322:352-8.
12. Moertel CG, Fleming TR, Macdonald JS, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995:122:321 -6.
13. Bilchik AJ, Hoon DS, Saha S, et al. Prognostic impact of micrometastases in colon cancer: interim results of a prospective multicenter trial. Ann Surg 2007;246:568-75; discussion 575-7.
14. Mamounas E,Wieand S, Wolmark N, et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03,and C-04). J Clin Oncol 1999;17:1349-55.
15. Quasar Collaborative G, Gray R, Barnwell J, et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study Lancet 2007;370:2020-9.
16. Benson AB III, Schrag D, Somerfield MR, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004;22:3408-19.
17. Sargent DJ, Wieand HS, Haller DG, et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2005;23:8664-70.
18. Punt CJ, Buyse M, Kohne CH, et al. Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials. J Natl Cancer Inst 2007;99:998-1003.
19. Sauter G, Simon R, Hillan K. Tissue microarrays in drug discovery. Nat Rev Drug Discov 2003;2:962-72.
20. Lindor NM, Burgart LJ, Leontovich O, et al. Immu-nohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol 2002;20:1043-8.
21. Zlobec I, Lugli A, Baker K, et al. Role of APAF-1, E-cadherin and peritumoral lymphocytic infiltration in tumour budding in colorectal cancer. J Pathol 2007;212: 260-8.
22. Zlobec I, Minoo P, Baumhoer D, et al. Multi-marker phenotype predicting adverse survival in patients with lymph node-negative colorectal cancer. Cancer 2008; 112:495-502.
23. Zlobec I, Terracciano L, Jass JR, Lugli A. Value of staining intensity in the interpretation of immunohistochemistry for tumor markers in colorectal cancer. Virchows Arch 2007;451:763-9.
24. Zlobec I, Steele R, Terracciano L, Jass JR, Lugli A. Selecting immunohistochemical cut-off scores for novel biomarkers of progression and survival in colorectal cancer. J Clin Pathol 2007;60:1112-6.
25. Sargent DJ, Goldberg RM, Jacobson SD, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001;345:1091 -7.
26. Wang Y, Jatkoe T, Zhang Y, et al. Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J Clin Oncol 2004;22: 1564-71.
27. Hase K, Shatney C, Johnson D, Trollope M, Vierra M. Prognostic value of tumor "budding" in patients with colorectal cancer. Dis Colon Rectum 1993;36: 627-35.
28. Jass JR, Love SB, NorthoverJM. A new prognostic classification of rectal cancer. Lancet 1987;1:1303-6.
29. Compton CC. Optimal pathologic staging: defining stage II disease. Clin Cancer Res 2007;13:6862-70s.
30. Ueno H, Murphy J, Jass JR, Mochizuki H, Talbot IC. Tumour "budding"as an index to estimate the potential of aggressiveness in rectal cancer. Histopathology 2002;40:127-32.
31. NakamuraT, Mitomi H, Kikuchi S, Ohtani Y, Sato K. Evaluation of the usefulness of tumor budding on the prediction of metastasis to the lung and liver after curative excision of colorectal cancer. Hepatogastroen-terology 2005;52:1432-5.
32. 3 colon cancer. Dis Colon Rectum 2003;46:1054-9.
33. BrabletzT, Jung A, Spaderna S, Hlubek F, Kirchner T. Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression. Nat Rev Cancer 2005;5:744 - 9.
34. Berger DH. Plasmin/plasminogen system in colorectal cancer. World J Surg 2002;26:767-71.
35. Hiendlmeyer E, Regus S, Wassermann S, et al. β-catenin up-regulates the expression of the urokinase plasminogen activator in human colorectal tumors. Cancer Res 2004;64:1209-14.
36. Brabletz T, Jung A, Hermann K, Gunther K, Hohen-berger W, Kirchner T. Nuclear overexpression of the oncoprotein β-catenin in colorectal cancer is localized predominantly at the invasion front. Pathol Res Pract 1998;194:701-4.
37. Prall F, Ostwald C. High-degree tumor budding and podia-formation in sporadic colorectal carcinomas with K-ras gene mutations. Hum Pathol 2007;38: 1696-702.
38. Prall F. Tumour budding in colorectal carcinoma. Histopathology 2007;50:151 -62.
39. Shinto E, Mochizuki H, Ueno H, Matsubara O, Jass JR. A novel classification of tumour budding in colorectal cancer based on the presence of cytoplasmic pseudo-fragments around budding foci. Histopathology 2005;47:25-31.
40. Baker K, Zlobec I, Tornillo L, Terracciano L, Jass JR, Lugli A. Differential significance of tumour infiltrating lymphocytes in sporadic mismatch repair deficient versus proficient colorectal cancers: a potential role for dysregulation of the transforming growth factor-β pathway. Eur J Cancer 2007;43:624-31.
41. Galizia G, Lieto E, Ferraraccio F, et al. Prognostic significance of epidermal growth factor receptor expression in colon cancer patients undergoing curative surgery. Ann Surg Oncol 2006;13:823-35.
42. Rosati G, Chiacchio R, Reggiardo G, De Sanctis D, Manzione L. Thymidylate synthase expression, p53, bcl-2, Ki-67 and p27 in colorectal cancer: relationships with tumor recurrence and survival. Tumour Biol 2004;25:258-63.
43. Cascinu S, Graziano F,Valentini M, et al. Vascular endothelial growth factor expression, S-phase fraction and thymidylate synthase quantitation in node-positive colon cancer: relationships with tumor recurrence and resistance to adjuvant chemotherapy. Ann Oncol 2001;12:239-44.